PHILADELPHIA - Lab-grown neural networks have the ability to replace lost axonal tracks in the brains of patients with severe head injuries, strokes or neurodegenerative diseases and can be safely delivered with minimal disruption to brain tissue, according to new research from Penn Medicine's department of Neurosurgical Research. Their work is published in the Journal of Neural Engineering.
Complex brain function derives from the activity of populations of neurons - discrete processing centers - connected by long fibrous projections known as axons. When these connections are damaged, by injury or diseases such as a Parkinson's or Alzheimer's disease, they, unlike many other cells in the body, have very limited capacity to regenerate, thus permanently disrupting the body's signal transmission and communication structure.
Senior author D. Kacy Cullen, PhD, an assistant professor of Neurosurgery and his team have been working to grow replacement connections, referred to as micro-tissue engineered neural networks (micro-TENNS), in the lab and test their ability to "wire-in" to replace broken axon pathways when implanted in the brain. Cullen's team advanced the micro-TENNs to consist of discrete populations of mature cerebral cortical neurons spanned by long axonal projections within miniature hair-like structures. These micro-TENNs are the first transplantable neural networks that mimic the structure of brain pathways in a miniature form.
In a previous 2015 publication in Tissue Engineering, Cullen and colleagues showed that preformed micro- TENNS could be delivered into the brains of rats to form new brain architecture that simultaneously replaced neurons as well as long axonal projections. "The micro-TENNS formed synaptic connections to existing neural networks in the cerebral cortex and the thalamus - involved in sensory and motor processing - and maintained their axonal architecture for several weeks to structurally emulate long-distance axon connections," Cullen reported. This work was the first to demonstrate that living micro-TENNS could successfully integrate into existing brain structures and reconstitute missing brain pathways, but, the team observed the need for improvement in how they were delivered to the brain, as this initial study required that the micro-TENNs be drawn into needles.
In response, the research team developed a new, less invasive delivery method by applying an ultra-thin coating to the micro-TENNs using a gel commonly found in food and biomedical products. This new biomaterial strategy allows the encapsulation of fully formed engineered neural networks for insertion into the brain without the use of a needle. "We searched for materials that could form a hard shell that would soften immediately following insertion to better match the mechanical properties of the native brain tissue," Cullen said. This, the team hypothesized, would minimize the body's reaction and improve the survival and integration of the neural networks. The additional coating was not detrimental to the number of surviving neurons, and the needleless method substantially reduces the implant footprint, suggesting that it would cause less damage and thus provide a more hospitable environment for implanted neurons to integrate with the brain's existing nervous system. "Additional research is required to directly test micro-TENN neuron survival and integration for each of these insertion methods," Cullen said.
Cullen and team plan to perfect their processes and further integrate neuroscience and engineering to come up with unique ways to aid patients suffering from brain injury or common neurodegenerative diseases such as Parkinson's and Alzheimer's disease.
"We hope this regenerative medicine strategy will someday enable us to grow individualized neural networks that are tailored for each patient's specific need," he said, "ultimately to replace lost neural circuits and improve brain function."
Funding for this study was provided by the National Science Foundation (Graduate Research Fellowship DGE-1321851), NIH (T32-NS043126 and T32-GM007517), and the Department of Veterans Affairs (RR&D Merit Review #B1097-I). The University of Pennsylvania has intellectual property covering this technology, and Dr. Cullen is an inventor.
Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania(founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $5.3 billion enterprise.
The Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 17 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $409 million awarded in the 2014 fiscal year.
The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center -- which are recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report -- Chester County Hospital; Lancaster General Health; Penn Wissahickon Hospice; and Pennsylvania Hospital -- the nation's first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Chestnut Hill Hospital and Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2014, Penn Medicine provided $771 million to benefit our community.